EFNA1 and neoplasm: Ephrin-A1 was reported to have no impact on clinical outcome in two studies [21,26], while a third study associated its overexpression with reduced smoking status, adenocarcinoma histological type, high level of tumor differentiation, and the presence of EGFR gene mutations, attributing to the ligand a positive influence in tumorigenesis [22].